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Dex is metabolized in liver microsomes by cytochrome P-450 2D6 (10). The major metabolite of dex is nordexfenfluramine (nordex). We have previously shown that dex causes pulmonary vasoconstriction through the inhibition of potassium channels, membrane depolarization, and the influx of extracellular calcium into the smooth muscle cells (SMCs) of resistance pulmonary arteries (PAs) (26) and that it might also cause the release of calcium from the sarcoplasmic reticulum (SR) (19) . We find that nordex causes greater pulmonary vasoconstriction than dex in both the isolated perfused rat lung and in PA rings. This enhanced vasoconstriction is largely mediated by 5-hydroxytryptamine type 2 (5-HT 2 ) receptors and release of calcium from the SR.
MATERIALS AND METHODS
All animal studies were approved by the Institutional Animal Care and Use Committee of the Minneapolis Veterans Affairs (VA) Medical Center and conform to current National Institutes of Health and American Physiological Society guidelines for the use and care of laboratory animals.
Isolated PA rings. Male Sprague-Dawley rats (250-350 g) were anesthetized with pentobarbital sodium (50 mg/kg), and their heart and lungs removed en bloc. The resistance PAs (4th-5th division) were dissected and immediately placed into ice-cold Earle's balanced salts solution of composition (in mM): 1.8 CaCl 2, 0.8 MgSO4, 5.4 KCl, 116.2 NaCl, 1.0 NaH2PO4, 5.6 glucose, and 26.2 NaHCO3. The vessels were cleaned of connective tissue cut into rings (4 mm in length). For some experiments the endothelium was mechanically denuded with the removal of endothelium demonstrated by the absence of normal relaxation response to acetylcholine (0.1-10 M). The rings were suspended between two stainless steel stirrups in organ chambers (Radnoti, Monrovia, CA) for the measurement of isometric force. The organ chambers were filled with 2 ml of Earle's balanced salt solution (37°C) and gassed with 20% O 2/5% CO2/balance N2, which resulted in PO2 values of 120-140 mmHg, PCO2 26-30 mmHg, and pH 7.35-7.45. The rings were equilibrated at a resting tension of 900 mg for at least 60 min and then exposed three times to phenylephrine (PE, 1 M) at 30-min intervals. The optimal resting tension was that which permitted the maximal constriction to 80 mM KCl in preliminary experiments. Ca 2ϩ -free Earle's balanced salt solution composition is (in mM): 0.8 MgSO4, 5.4 KCl, 118 NaCl, 1.0 NaH2PO4, 5.6 glucose, and 26.2 NaHCO3.
After a further 30 min, nordex or dex was given at concentrations of 1, 3, 10, 30, and 100 M at 4-min intervals. In other series of rings, to test their effects on nordex-induced constriction, ketanserin, 2-aminoethoxydiphenyl borate (2-APB), or nifedipine was given 5 min before the administration of 10 M nordex. In additional studies, we eliminated the calcium in the bath solution 1 min before the nordex by switching solutions.
Isolated perfused lung model. Male Sprague-Dawley rats were anesthetized and intubated with PE-200 tubing (inner diameter 1.44 mm, outer diameter 1.90 mm), a thoracotomy was performed, and the animal was heparinized (100 units). The PA was cannulated with a double-lumen cannula so that pressure measurements and perfusion could be obtained simultaneously. The left atrium was cannulated for efferent flow in a recirculating manner at a rate of 0.04 ml⅐min Ϫ1 ⅐g body wt Ϫ1 . Krebs solution (50 ml) containing 4% albumin and 5 g/ml of meclofenamate was used for the perfusate. The lungs were ventilated with humidified gases containing 20% O 2/5% CO2/balance N2 (normoxia) or 2.5% O2/5% CO2/balance N2 (hypoxia). The lung chamber and perfusate were maintained at 37°C. Respiration was set to physiological values (frequency 70 breaths/min, tidal volume 1.5 ml), with a positive end-respiratory pressure of 2.5 cmH 2O. To determine lung reactivity, we subjected the lungs to two consecutive cycles, each consisting of 10 min of normoxia, a bolus injection of angiotensin II (0.15 g) into the afferent line, and, after 8 min, a 6-min hypoxic challenge. Lungs were accepted for study only if they had a baseline pressor response Ͼ8 mmHg to hypoxia. After return to baseline, the lungs were given a nitric oxide synthase inhibitor (N-nitro-L-arginine methyl ester, 50 M) and perfused for a further 20 min. At this point, increasing doses of the test drugs dex or nordex (1, 10, and 100 M) were administered at 5-min intervals. The 5-HT 2 receptor antagonist ketanserin (1 M) or vehicle was then administered. We have found that this concentration of ketanserin prevents the vasoconstriction caused by 100 M serotonin (data not shown).
Cell isolation. Rat pulmonary artery smooth muscle cells (PASMCs) were dispersed fresh on each day of experimentation. Resistance PAs (ϳ200 m diameter, 4th or 5th division) were dissected and placed in "Ca 2ϩ -free" Hanks' solution for 10 min at 4°C. The Hanks' solution contained (in mM) 140 NaCl, 4.2 KCl, 1.2 KH 2PO4, 0.5 MgCl2, 10 HEPES, and 0.1 EGTA (pH 7.4). Arteries were then transferred to a solution containing 1 mg/ml papain, 0.75 mg/ml bovine albumin, and 0.85 mg/ml dithiothreitol and digested at 4°C for 30 min and then at 37°C for 13 min. Arteries were washed thoroughly with Hanks' solution without EGTA ("low-Ca 2ϩ ") for at least 10 min and then maintained on ice in Hanks' supplemented with 1 mg/ml glucose. Several digestions were done each day to ensure cell viability. This digestion protocol consistently produced high yields of viable, relaxed SMC.
Electrophysiology. Triturated cells were divided into aliquots on the stage of an inverted microscope (Nikon Diaphot 200) for conventional whole cell patch-clamp studies. After a brief period to allow partial adherence to the bottom of the recording chamber, cells were perfused with a normoxic solution of composition (in mM): 115 NaCl, 25 NaHCO 3, 4.5 KCl, 1 KH2PO4, 1.5 CaCl2, 0.5 MgCl2, 10 HEPES, and 10 glucose (pH 7.4 with NaOH, PO2Ϸ120 mmHg by bubbling with 21% O 2/5% CO2/balance N2). Electrode resistances ranged from 3 to 5 m⍀ after fire polishing and when filled with a solution of composition (in mM) 140 KCl, 1.0 MgCl 2, 10 HEPES, and 1 EGTA (pH 7.2 with KOH).
The patch-clamp amplifiers were Axopatch 200A and B (Axon Instruments, Foster City, CA) in all voltage-and current-clamp experiments. Offset potentials were nulled directly before formation of a seal. Capacitance and series resistance were corrected (usually 80%). No leak subtraction was made. Leakage current was monitored using hyperpolarizing steps (Ϫ30 mV) from the holding potential, a procedure that did not activate ion channels but allowed measurement of passive membrane properties and leak during the experiments. Cells expressing holding current at Ϫ70 mV of Ͼ20 pA before or during the recordings were discarded. The extracellular perfusate perfusion rate was 2 ml/min. Cells were voltage clamped at a holding potential of Ϫ70 mV, and currents were evoked by ϩ20 mV steps to more positive potentials using test pulses of 200-ms duration at a rate of 0
Measurement of intracellular Ca 2ϩ . Cytosolic calcium concentration ([Ca 2ϩ ] i) was measured by dual-excitation imaging using fura 2 (9). Single PASMCs were prepared as for patch-clamp experiments, transferred to imaging dishes (Molecular Probes, Eugene, OR), and incubated in low-Ca 2ϩ Hanks' solution with the cell-permeable acetoxymethyl ester form of fura 2 (0.1 M) and Pluronic F-127 (0.8 M) for 15 min at room temperature (15) . The plates were then washed with HEPES buffer (see solution composition in Electrophysiology) containing 1.5 mM Ca 2ϩ and incubated at room temperature for a further 20 min. The plates were then washed again and placed on the microscope stage. The drugs were added directly to the cells as a bolus by microinjection. All drugs were given in 10-l volumes to remove potential volume-induced artifacts. Saline injections of 10 l had no effect on [ 
, where Kd is the dissociation constant, Fo is the maximal 380-nm signal intensity, Fs is the minimal 380-nm signal intensity, and R is the ratio of 340-nm fluorescence to 380-nm fluorescence. Any cells not responding to ionomycin were discarded, as were cells showing significant photo bleaching. Peak increases in [Ca 2ϩ ]i were measured during each intervention, and data are given as averaged peak values.
Drugs. Nordex, dex, and ketanserin were obtained from RBI (Natick, MA). All other drugs and salts were obtained from Sigma (St. Louis, MO) except fura 2-AM (Molecular Probes). All the drugs were dissolved in normal saline, except ketanserin and nifedipine, which were dissolved in ethanol, and 2-APB, cyclopiazonic acid (CPA), fura 2, Pluronic F-127, and ionomycin, which were dissolved in DMSO as a stock solution. Vehicle controls were done for all experiments.
Statistics. The contractions for the ring experiments are expressed as a percentage of the contraction developed by 1 M PE. Values are expressed as the means Ϯ SE. Intergroup differences were assessed by a factorial ANOVA with post hoc analysis with Fisher's least significant different difference test (StatView II, version 4.0, Abacus Concepts). A paired t-test was used for evaluation of differences within groups. P Ͻ 0.05 was considered statistically significant. (Fig. 1) . The effect of nordex on PA ring tension was not affected by the denudation of endothelium (Fig. 2) .
RESULTS

Isolated
The effect of nordex (10 M) on PA ring tension (both intact and denuded) was almost completely inhibited (from 32.0 Ϯ 3.8, 35.5 Ϯ 5.3% to 0.1 Ϯ 1.9, 1.4 Ϯ 1.6% of PE contraction) by the nonspecific 5-HT 2 receptor antagonist ketanserin (1 M) (Fig. 3) .
The contraction caused by nordex was dose dependently inhibited by 2-APB, a blocker of store-operated calcium channels (SOCs) and the inositol 1,4,5-trisphosphate (IP 3 ) receptors. The blockade was 56.7 Ϯ 9.3% following the administration of 10 M 2-APB (Fig. 4) . Omitting bath calcium or adding 1 M nifedipine inhibited 59.8 Ϯ 8.5 and 62.9 Ϯ 3.9% of the nordex contraction, respectively. Similarly, depleting SR calcium with 30 M CPA almost completely inhibited the nordex-induced contraction (Fig. 4) . CPA at 30 M has no effect on the contraction of 60 mM KCl (372 Ϯ 52 vs. 362 Ϯ 38 mg, n ϭ 9). The combination of 1 M nifedipine and 10 M 2-APB completely inhibited the contraction induced by nordex (Fig. 4) . (Fig. 5) .
Electrophysiology. Patch-clamp studies in isolated PASMCs found that K ϩ currents and E m were not significantly affected by 10 M nordex (n ϭ 5) (Fig. 6A) or 100 M nordex (data not shown). The inhibition of K ϩ current by dex (100 M) was the same in the presence and absence of ketanserin (1 M) (data not shown, n ϭ 5 for both groups). The outward K ϩ current and resting E m of PASMCs were not significantly affected by 10 M (n ϭ 4) (Fig. 6B) ] i (Fig. 7) .
DISCUSSION
Nordex is a more potent pulmonary vasoconstrictor than dex. The greater ability of nordex to cause vasoconstriction in the isolated lung or contraction of PA rings can be prevented by pretreatment with ketanserin, suggesting that it is mediated by 5-HT 2 receptors. The observation is strengthened by the finding that ketanserin entirely prevents the rise in cytosolic calcium produced by nordex. The enhanced contraction that nordex stimulates in PA rings is not diminished by removal of endothelium, indicating that it is the result of a direct effect on the smooth muscle, rather than the result of the release of endothelium-derived substances such as endothelin or thromboxane A 2 . The concentrations of dex and nordex that were demonstrated to cause acute vasoconstriction in the isolated lung and PA ring (10 M) are close to those in the blood of patients taking dex over a long time (0.1-1 M).
The effect of zero calcium outside the SMC indicates that ϳ60% of the increase in cytosolic calcium induced by nordex enters from outside the cell. The effect of 2-APB would suggest that the remainder of the increase in calcium probably comes from the SR. This two-component model for the increase in cytosolic calcium is similar to that described in the response to 5-HT (27) . It is possible that 2-APB may have effects in addition to blocking SOCs and the IP 3 receptor (3), but the electrophysiology experiments described here make it unlikely that it has an effect on potassium current or E m (Fig.  6 ). The specificity of 2-APB is reinforced by the observation that it did not reduce the pressor response to KCl (60 mM) in isolated perfused rat lungs (data not shown, n ϭ 5) or the contraction to 60 mM KCl in the PA rings (data not shown, n ϭ 6). The observation that nifedipine inhibits much of the increase in cytosolic calcium caused by nordex might be thought to implicate L-type calcium channels. However, although dex inhibits potassium current and causes membrane depolarization in PASMCs (16, 26) , nordex surprisingly had no effect on potassium current or on E m . This apparent impasse may be explained by the report that the same concentration of nifedipine (1 M) can also block the SOCs that replete the SR (6) . Other papers support the concept that dihydropyridine agents, such as nifedipine, can inhibit SOCs as well as voltagegated L-type calcium channels (4, 11, 28) . Consequently these data would suggest that the vasoconstriction caused by nordex is the result of calcium release from the SR and calcium entry/repletion through the SOCs and not through voltagegated L-type calcium channels. This interpretation is strengthened by the observation that prior treatment of PA rings with CPA to release SR stores of calcium will markedly inhibit nordex-induced contraction while leaving the contraction to KCl unchanged.
There is considerable evidence that dex and nordex can act as agonists at the 5-HT 2B receptor (7, 13, 22) . Although dex binds weakly, nordex shows a high affinity for the human 5-HT 2B receptor (7, 22) . The subsequent signaling cascade involves G proteins, phospholipase C, IP 3 , and diacylglycerol (25) . Dex given chronically to hypoxic mice, with sufficient time for metabolism to nordex, increases right ventricular pressure and pulmonary vascular muscularization (13) . These effects of both hypoxia and dex are markedly inhibited in mice lacking the 5-HT 2B gene. Thus it appears that a large part of the hemodynamics and vascular remodeling seen in response to dex/nordex is mediated by 5-HT 2B receptor. When dex is given acutely (5 min before hypoxia), there is no increase in measured levels of plasma nordex and only a small increase (ϳ2 mmHg) in the hypoxic pressor response (13) , which is the same in the genetically altered mice. It is also important to note that the vasoconstriction caused by dex in the isolated rat lung (Fig. 5) is not decreased by ketanserin. These observation are compatible with the concept that dex acts through inhibition of K ϩ current and membrane depolarization (16, 26) , whereas nordex acts through the 5-HT 2B receptors. This conclusion is also compatible with the finding of Belohlavkova et al. (2) , who reported a nonspecific 5-HT 2 blocker, ritanserin, inhibited much of the vasoconstriction caused by fenfluramine in the isolated lung. These separate pathways mean that dex would enhance Ca 2ϩ entry through the L-type calcium channel, whereas nordex would increase cytosolic Ca 2ϩ as a result of SR release and SOC replenishment. The ability of nifedipine to block both L-type calcium channels and SOCs, discussed earlier, may provide an explanation of the efficacy of nifedipine in the treatment of some PPH patients (20, 21) . As the level of cytosolic calcium is an important signal, not only for vasoconstriction but also for proliferation (17) , new therapeutic approaches to PPH may involve specific SOC blockers, the combination of nifedipine with such blockers and the use of 5-HT 2B blockers.
